Live Analyst Rating Changes 25645 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jeet Mukherjee
BTIG

Jeet Mukherjee

BTIG
Wall Street Analyst
★★★☆☆
#1681
on 13Foresight · ranked by our own returns
64%
Success Rate
+11.9%
Average Return
32 of 50 calls profitable · +75.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 64% of Jeet Mukherjee's ratings turned a profit when each position was held for 2 year — averaging +11.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

107 Buy 2 Hold 0 Sell
Jeet's Stock Coverage 25 ratings · 2026-08-19
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
AVBP
ArriVent BioPharma, Inc.
 Aug 12, 2026 BUY Strong Buy
+42.4% avg upside
15 analysts
$42.00
42.69% Upside
 -7.8% ·
AARD
Aardvark Therapeutics, Inc.
 Aug 12, 2026 HOLD Buy
+211.2% avg upside
12 analysts
 — -0.5% ·
BCAX
Bicara Therapeutics Inc.
 Aug 12, 2026 BUY Strong Buy
+27.8% avg upside
15 analysts
$39.00
55.53% Upside
 +1.2% ·
IPHA
Innate Pharma
 Aug 12, 2026 BUY Strong Buy
+239.4% avg upside
10 analysts
$9.00
326.32% Upside
 -11.7% ·
MNPR
Monopar Therapeutics Inc
 Aug 12, 2026 BUY Strong Buy
-12.1% avg upside
18 analysts
$133.00
15.38% Upside
 +3.6% ·
CATX
Perspective Therapeutics
 Aug 11, 2026 BUY Strong Buy
+241.9% avg upside
22 analysts
$14.00
336.86% Upside
 +0.6% ·
FTH
Faeth Therapeutics
 Aug 10, 2026 BUY Strong Buy
+35.8% avg upside
16 analysts
$55.00
67.33% Upside
 +13.2% ·
FHTX
Foghorn Therapeutics
 Aug 06, 2026 BUY Strong Buy
+77.1% avg upside
17 analysts
$11.00
63.42% Upside
 +12.4% ·
VSTM
Verastem
 Aug 06, 2026 BUY Strong Buy
+106.5% avg upside
24 analysts
$18.00
139.03% Upside
 +11.3% ·
PVLA
Palvella Therapeutics
 Aug 04, 2026 BUY Strong Buy
+11.1% avg upside
27 analysts
$215.00
39.74% Upside
 +2.7% ·
IBRX
ImmunityBio
 Aug 04, 2026 BUY Strong Buy
+45.6% avg upside
12 analysts
$12.00
54.44% Upside
 +14.0% ·
NRIX
Nurix Therapeutics
 Jul 01, 2026 BUY Strong Buy
+19.9% avg upside
28 analysts
$32.00
19.30% Upside
 +13.6% ·
KYMR
Kymera Therapeutics
 Jun 25, 2026 BUY Strong Buy
-13.0% avg upside
37 analysts
$134.00
11.85% Upside
 +4.2% ·
AAPG
Ascentage Pharma Group International Unsponsored ADR
 May 13, 2026 BUY Strong Buy
+154.9% avg upside
10 analysts
$48.00
163.75% Upside
 -11.1% ·
ARVN
Arvinas Holding Company
 May 13, 2026 BUY Buy
+208.9% avg upside
28 analysts
$18.00
94.43% Upside
 -6.4% ·
VKTX
Viking Therapeutics
 May 01, 2026 BUY Strong Buy
+115.1% avg upside
31 analysts
$125.00
272.82% Upside
 +10.6% ·
LYRA
Lyra Therapeutics
 Jun 03, 2025 HOLD Hold
+64688.7% avg upside
7 analysts
 — · ·
KURA
Kura Oncology
 May 23, 2025 HOLD Strong Buy
+113.9% avg upside
26 analysts
 — +92.5% ·
LEGN
Legend Biotech
 May 23, 2025 BUY Strong Buy
+187.3% avg upside
27 analysts
$91.00
336.62% Upside
 -29.5% ·
TCRX
TScan Therapeutics
 May 21, 2025 BUY Strong Buy
+947.9% avg upside
12 analysts
$12.00
1418.80% Upside
 -40.9% ·
ELVN
Enliven Therapeutics
 May 13, 2025 BUY Strong Buy
+0.1% avg upside
16 analysts
$42.00
29.69% Downside
 +193.7% ·
JANX
Janux Therapeutics Inc
 May 09, 2025 BUY Strong Buy
+177.4% avg upside
21 analysts
$100.00
513.58% Upside
 -36.4% ·
BCAB
BioAtla
 May 07, 2025 BUY Strong Buy
+2950.2% avg upside
13 analysts
$10.00
232.27% Upside
 -86.2% ·
IDYA
IDEAYA Biosciences
 Apr 14, 2025 BUY Strong Buy
+29.0% avg upside
29 analysts
$62.00
68.63% Upside
 +113.6% ·
CARM
Carisma Therapeutics
 Apr 01, 2025 HOLD Buy
+127073.9% avg upside
11 analysts
 — -99.1% ·
🔒 20 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jeet Mukherjee — Frequently Asked Questions
How accurate are Jeet Mukherjee's stock ratings?
Based on the calls 13Foresight could measure, about 64% of Jeet's ratings were profitable over a one-year hold, with an average return of +11.2% per rating, or +53.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jeet ranked on 13Foresight?
Jeet Mukherjee is currently ranked #1681 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jeet cover?
Jeet most recently has ratings on AVBP, AARD, BCAX, IPHA, MNPR, CATX, FTH, FHTX, VSTM, PVLA, IBRX, NRIX and 13 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.